Previous 10 | Next 10 |
DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it will participate in the Virtual Investor Innovation in Dermatology Spotlight event on Tuesday, April 26, 2022, at 2:00 PM ET. For the ...
DURHAM, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from its pivotal Phase 3 study of berdazimer gel 10.3% (SB206) for the treatment of molluscum contagiosum was selected for an oral pr...
DURHAM, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will be presenting at two upcoming investor conferences. The d...
EVENING POST GROUP SELLS EPI HEALTH TO NOVAN, INC PR Newswire CHARLESTON, S.C. , March 11, 2022 /PRNewswire/ -- Evening Post Group ("EPG"), a family-owned operating group based in Charleston, South Carolina , is excited to announce the successful sale of EPI ...
Novan (NASDAQ:NOVN) is acquiring EPI Health, LLC, a specialty pharmaceutical company focused on the U.S. dermatology market. The transaction involves upfront purchase price of $27.5M, consisting of $11M and $16.5M in a seller’s note with a 24-month term. Based on financial performance ...
– EPI Health promotes four prescription products posting 2021 operating revenue of $17.6 million – – Acquisition forward integrates Novan with complementary commercial infrastructure to drive commercial launch of SB206, subject to regulatory approval, for th...
Novan, Inc. (NOVN) Q4 Earnings Conference Call February 22, 2022 8:30 AM ET Company Participants Paula Brown Stafford - Chairman and Chief Executive Officer John M. Gay - Chief Financial Officer Conference Call Participants Jonathan Aschoff - Roth Capital Jennifer Kim - Cantor Fitzgerald Oren...
Novan press release (NASDAQ:NOVN): Q4 GAAP EPS of -$1.74. Revenue of $2.96M (-39.8% Y/Y). The Company reported a cash and cash equivalents balance of $47.1 million as of December 31, 2021. For further details see: Novan GAAP EPS of -$1.74, revenue of $2.96M
– First New Drug Application (NDA) submission targeted in Q4 2022 for lead program SB206 (berdazimer gel 10.3%) for molluscum contagiosum – – Ongoing advancement of priority development pipeline assets SB019, for the treatment of SARS-CoV-2, toward a Phase 1...
BLD,BRSP,CBRL,CEQP,CFX,CNP,DFIN,ESPR,ETRN,EXPD,FLR,HD,HEP,HL,HR,KBR,LPX,M,MDT,MIDD,NOVN,NSA,NXST,SBRA,SOHU,TPB,TPX,TRU,WLK,WLKP For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Tuesday's open
News, Short Squeeze, Breakout and More Instantly...
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward...
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6...
– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress ...